Deutsche Bank AG decreased its position in shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) by 11.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 184,766 shares of the company’s stock after selling 23,241 shares during the quarter. Deutsche Bank AG owned 0.42% of Biohaven Pharmaceutical worth $6,832,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in BHVN. Stifel Financial Corp lifted its holdings in Biohaven Pharmaceutical by 555.2% in the fourth quarter. Stifel Financial Corp now owns 2,719,538 shares of the company’s stock valued at $100,569,000 after acquiring an additional 2,304,438 shares during the period. Brown Advisory Inc. acquired a new position in Biohaven Pharmaceutical in the fourth quarter valued at approximately $16,766,000. TIAA CREF Investment Management LLC lifted its holdings in Biohaven Pharmaceutical by 670.0% in the third quarter. TIAA CREF Investment Management LLC now owns 463,254 shares of the company’s stock valued at $17,395,000 after acquiring an additional 403,092 shares during the period. Aisling Capital Management LP acquired a new position in Biohaven Pharmaceutical in the fourth quarter valued at approximately $10,151,000. Finally, Samlyn Capital LLC lifted its holdings in Biohaven Pharmaceutical by 32.8% in the fourth quarter. Samlyn Capital LLC now owns 921,536 shares of the company’s stock valued at $34,078,000 after acquiring an additional 227,432 shares during the period. 88.91% of the stock is owned by institutional investors.

Shares of BHVN stock opened at $60.16 on Monday. The company has a market cap of $2.66 billion, a PE ratio of -9.78 and a beta of 0.50. Biohaven Pharmaceutical Holding Co Ltd has a 1-year low of $25.60 and a 1-year high of $62.25.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its earnings results on Thursday, February 28th. The company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.06). Research analysts anticipate that Biohaven Pharmaceutical Holding Co Ltd will post -6.21 earnings per share for the current year.

In other news, Director Declan Doogan sold 2,078 shares of the company’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $45.48, for a total transaction of $94,507.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Julia P. Gregory sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, February 21st. The stock was sold at an average price of $43.56, for a total value of $522,720.00. Following the transaction, the director now directly owns 12,000 shares of the company’s stock, valued at $522,720. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 437,856 shares of company stock valued at $22,279,475. Corporate insiders own 34.20% of the company’s stock.

A number of research analysts have issued reports on BHVN shares. Morgan Stanley downgraded Biohaven Pharmaceutical from an “overweight” rating to an “equal weight” rating and set a $49.13 price target for the company. in a report on Tuesday, April 9th. They noted that the move was a valuation call. Cantor Fitzgerald reissued a “buy” rating and issued a $75.00 price target on shares of Biohaven Pharmaceutical in a report on Friday, February 8th. Zacks Investment Research raised Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a report on Tuesday, January 15th. ValuEngine raised Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $56.00 price target (up from $48.00) on shares of Biohaven Pharmaceutical in a report on Monday, March 4th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $62.57.

WARNING: This article was first posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.watchlistnews.com/deutsche-bank-ag-decreases-position-in-biohaven-pharmaceutical-holding-co-ltd-bhvn/2980557.html.

Biohaven Pharmaceutical Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Article: Understanding Average Daily Trade Volume

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.